# Cinchona pubescens (Cinchona pubescens Vahl.)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/cinchona-pubescens-cinchona-pubescens-vahl
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** South American
**Also Known As:** Cinchona pubescens Vahl., Red Cinchona, Quinine Bark, Cascarilla Roja, Fever Bark, Cinchona succirubra (historical synonym)

## Overview

Cinchona pubescens stem bark contains quinoline alkaloids—principally quinine, quinidine, cinchonine, and cinchonidine—which inhibit heme detoxification in Plasmodium parasites and suppress NF-κB [inflammatory](/ingredients/condition/inflammation) signaling. In vitro, methanol bark extract demonstrates potent [antioxidant activity](/ingredients/condition/antioxidant) with DPPH• scavenging IC50 of 14.86 µg/mL, outperforming α-tocopherol (37.15 µg/mL), though no dedicated human clinical trials for the species as a supplement have been published.

## Health Benefits

- **Antimalarial Activity**: Quinoline alkaloids, particularly quinine, inhibit hemozoin biocrystallization in Plasmodium falciparum by accumulating in the parasite's digestive vacuole and blocking heme detoxification, producing lethal oxidative stress for the parasite.
- **[Antioxidant Protection](/ingredients/condition/antioxidant)**: Methanol stem bark extracts exhibit DPPH• radical scavenging with an IC50 of 14.86 µg/mL and ABTS•+ scavenging at IC50 12.04 µg/mL, both significantly outperforming the reference antioxidant α-tocopherol (37.15 µg/mL and 38.45 µg/mL, respectively), attributable to high phenolic content including p-hydroxybenzoic acid at 40.06 mg/g.
- **Anti-inflammatory Effects**: The quinuclidine alkaloid scaffold and phenolic compounds such as 2(1H)-quinolinone (identified at 11.95% peak area by GC-MS in related Cinchona species) suppress the NF-κB signaling pathway, potentially reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation) production.
- **Cytotoxic / Anticancer Potential**: In vitro Alamar blue assays show methanol extract cytotoxicity against HT-29 colorectal cells (IC50: 69.99 µg/mL), HeLa cervical cells (IC50: 57.99 µg/mL), and HepG2 hepatocellular cells (IC50: 146.10 µg/mL), with proposed mechanisms involving alkaloid-mediated apoptotic pathway activation.
- **Metal Chelation**: Phenolic hydroxyl groups in the bark extract coordinate divalent metal ions via phosphomolybdenum reduction and chelation reactions, which may reduce oxidative damage driven by free iron and copper in tissue.
- **Antipyretic and Fever Management**: Historically, Cinchona bark is the original source of quinine used to reduce malarial fevers; quinoline alkaloids modulate hypothalamic temperature regulation and inflammatory mediators, providing the pharmacological basis for its classical antipyretic reputation.
- **[Cardiovascular](/ingredients/condition/heart-health) Ion Channel Modulation**: Quinidine, a primary alkaloid in Cinchona bark, acts as a class IA antiarrhythmic agent by blocking cardiac sodium channels and prolonging the action potential, though therapeutic use requires precise pharmaceutical-grade dosing due to a narrow safety window.

## Mechanism of Action

The principal antimalarial mechanism of quinine and related quinoline alkaloids involves accumulation within the acidic digestive vacuole of Plasmodium parasites, where the protonated alkaloid inhibits the biocrystallization of toxic free heme into inert hemozoin, leading to lethal heme-mediated oxidative damage to the parasite membrane. At the molecular level, the quinuclidine ring's basic nitrogen and the adjacent methylene alcohol group of quinine facilitate intercalation and complex formation with ferriprotoporphyrin IX, preventing its detoxification and generating [reactive oxygen species](/ingredients/condition/antioxidant) within the parasite. Anti-inflammatory activity is mediated through suppression of NF-κB pathway activation, reducing downstream transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including TNF-α and IL-6, an effect attributed to both the quinoline alkaloids and phenolic constituents such as p-hydroxybenzoic acid and 2(1H)-quinolinone. Antioxidant effects operate through direct free radical scavenging by phenolic hydroxyl groups, metal ion chelation reducing Fenton reaction-derived ROS, and phosphomolybdenum reduction capacity, collectively protecting cellular lipids and proteins from oxidative damage.

## Clinical Summary

No randomized controlled trials or formal clinical investigations specifically targeting Cinchona pubescens as a supplement or botanical ingredient have been published as of the current literature review. The clinical pharmacology of isolated quinine—derived from Cinchona species broadly—is well-characterized through decades of pharmaceutical research, including WHO-recognized antimalarial efficacy, but this represents purified pharmaceutical-grade alkaloid data rather than whole-extract supplementation. In vitro cytotoxicity outcomes for C. pubescens bark extracts (HeLa IC50: 57.99 µg/mL; HT-29 IC50: 69.99 µg/mL) are preliminary and not supported by dose-response studies in animal models or phased clinical trials. Confidence in recommending C. pubescens as a self-administered supplement for any indication remains very low due to the absence of clinical evidence, variability in alkaloid content across preparations, and the known toxicity risks of its primary alkaloids at uncontrolled doses.

## Nutritional Profile

Cinchona pubescens stem bark is not a significant dietary nutrient source and is not consumed as a food ingredient. Its primary phytochemical profile includes quinoline alkaloids (quinine, quinidine, cinchonine, cinchonidine) comprising 6–15% of dry bark weight across plant parts, with young leaves contributing over 1% alkaloids. Phenolic compounds are well-represented: p-hydroxybenzoic acid at 40.06 mg/g in methanol extract and 9.29 mg/g in water extract; total phenolic content in aqueous C. officinalis bark extract is approximately 0.548 mg/100 mg dry weight. GC-MS identification of related species reveals 2,4-di-tert-butylphenol (12.24% peak area), 2(1H)-quinolinone (11.95%), and 4-ethoxy-2-(methylamino)tropone (3.18%) as additional bioactive constituents. Bioavailability of alkaloids is improved significantly through nanoparticle encapsulation compared to aqueous extraction, which yields lower alkaloid solubilization due to the hydrophobic character of the quinoline ring system.

## Dosage & Preparation

- **Traditional Bark Decoction**: Dried stem bark simmered in water for 15–20 minutes; historically consumed as a bitter tea for fever management, though alkaloid concentration is highly variable and uncontrolled.
- **Methanol/Ethanol Extract (Laboratory/Research Grade)**: Used in in vitro studies at concentrations of 14.86–146 µg/mL for [antioxidant](/ingredients/condition/antioxidant) and cytotoxic assays; no standardized commercial supplemental dose derived from these parameters.
- **Standardized Pharmaceutical Quinine**: Isolated via ethanol extraction followed by silica gel column chromatography; pharmaceutical quinine sulfate tablets are dosed at 650 mg three times daily for 3–7 days for uncomplicated malaria (adult prescription dosing), strictly distinct from supplement use.
- **Nanoparticle-Loaded Extract**: Experimental formulations using FeCl3-mediated nanoparticle synthesis enhance intracellular bioavailability of alkaloids and phenolics in laboratory settings; not commercially available.
- **Standardization Note**: Total alkaloid content varies widely (6–15% across plant parts); no standardized supplement form with verified alkaloid percentage is currently validated for C. pubescens specifically.
- **Timing and Caution**: Any preparation containing quinoline alkaloids should be used only under medical supervision due to cinchonism risk; self-supplementation is not recommended without clinical guidance.

## Safety & Drug Interactions

Cinchona pubescens alkaloids carry a well-documented toxicity profile; cinchonism—characterized by tinnitus, headache, nausea, vomiting, visual disturbances, and cardiac arrhythmias—can occur even at therapeutic quinine doses, and overdose may cause severe hypoglycemia, hemolytic anemia, and cardiac conduction abnormalities including QT prolongation. In vitro cytotoxicity was observed on normal human cell lines HEK-293 (embryonic kidney) and THLE-2 (hepatic) in parallel with cancer cell line effects, indicating a dose-dependent risk to healthy tissues at concentrations approaching therapeutic range. Critical drug interactions include potentiation of warfarin anticoagulation (quinine inhibits CYP2C9), increased risk of arrhythmia with QT-prolonging drugs (macrolides, fluoroquinolones, antipsychotics), elevated digoxin plasma levels (P-glycoprotein inhibition), and hypoglycemic potentiation with insulin or sulfonylureas. Cinchona preparations are contraindicated in pregnancy (quinine is a uterine stimulant and historically used as an abortifacient), in patients with G6PD deficiency (risk of hemolytic crisis), myasthenia gravis, optic neuritis, and hypersensitivity to quinoline compounds; breastfeeding women should avoid use due to alkaloid transfer in breast milk.

## Scientific Research

The evidence base for Cinchona pubescens as a discrete supplemental ingredient is limited to in vitro preclinical studies; no published human clinical trials specifically investigating C. pubescens as a nutritional or medicinal supplement were identified in available literature. In vitro [antioxidant](/ingredients/condition/antioxidant) studies using DPPH• and ABTS•+ assays demonstrate consistently potent radical scavenging for methanol bark extracts (IC50 values of 14.86 and 12.04 µg/mL, respectively), superior to α-tocopherol reference standards, but these do not translate directly to clinical bioavailability or in vivo efficacy. Cytotoxicity data against HT-29, HeLa, and HepG2 cancer cell lines (IC50 range: 57.99–146.10 µg/mL) provides preliminary mechanistic interest but lacks confirmation in animal models or human studies; notably, cytotoxic effects were also observed on normal cell lines HEK-293 and THLE-2, raising selectivity concerns. The broader historical and pharmacological literature on purified quinine from Cinchona species is extensive and forms the basis for pharmaceutical antimalarial drugs, but this body of evidence should not be conflated with evidence for whole-plant C. pubescens supplementation.

## Historical & Cultural Context

Cinchona bark, including C. pubescens and its close relatives, holds one of the most significant places in medical history as the original source of quinine, the first effective treatment for malaria. Indigenous Quechua peoples of the Andes reportedly used the bark to treat fevers, and the remedy was introduced to European medicine in the early 17th century—most famously credited, though likely apocryphally, to the Countess of Chinchon in Peru around 1638—subsequently reshaping colonial medicine and global public health. The bark was so strategically important that European colonial powers, particularly Britain and the Netherlands, smuggled seeds and established large-scale plantations in Java and Ceylon during the 19th century to secure supply for tropical empire administration. The genus name Cinchona itself is derived from the Countess legend, and the isolation of pure quinine from the bark in 1820 by French chemists Pelletier and Caventou marked a pivotal moment in alkaloid chemistry and pharmacognosy.

## Synergistic Combinations

Historically, Cinchona quinine has been combined with doxycycline or clindamycin in pharmaceutical antimalarial regimens, where the combination exploits complementary mechanisms—quinine's heme detoxification inhibition paired with antibiotic-mediated aporiblast protein synthesis suppression—to reduce resistance emergence and improve parasitic clearance. The antioxidant phenolics in Cinchona bark, particularly p-hydroxybenzoic acid, may exhibit additive or synergistic [free radical scaveng](/ingredients/condition/antioxidant)ing when combined with other polyphenol-rich botanicals such as green tea extract (EGCG) or grape seed proanthocyanidins, though this pairing has not been studied specifically for C. pubescens. In traditional Amazonian and Andean herbalism, Cinchona bark was sometimes paired with aromatic bitters and warming herbs (e.g., ginger, cinnamon) to offset gastrointestinal irritation and improve palatability of the intensely bitter alkaloid-rich decoction.

## Frequently Asked Questions

### What is Cinchona pubescens used for?

Cinchona pubescens bark has been used since the 17th century as the primary botanical source of quinine for treating malaria and fevers. Its stem bark contains 6–15% quinoline alkaloids—including quinine, quinidine, cinchonine, and cinchonidine—that inhibit heme detoxification in Plasmodium parasites. Modern research also explores its antioxidant and potential anticancer properties, though no clinical trials have validated it as a standalone dietary supplement.

### Is Cinchona pubescens safe to take as a supplement?

Cinchona pubescens is not considered safe for unsupervised self-supplementation due to the narrow therapeutic window of its quinoline alkaloids, which can cause cinchonism (tinnitus, nausea, arrhythmia) even at modest doses. In vitro studies confirmed cytotoxic effects on normal human cell lines (HEK-293 and THLE-2) alongside cancer cells, indicating tissue toxicity risk at higher concentrations. It is contraindicated in pregnancy, G6PD deficiency, and myasthenia gravis, and interacts dangerously with anticoagulants, antiarrhythmics, and QT-prolonging medications.

### How does quinine from Cinchona bark kill malaria parasites?

Quinine accumulates in the acidic digestive vacuole of Plasmodium parasites where it forms a complex with ferriprotoporphyrin IX (toxic free heme), blocking its conversion into inert hemozoin crystals. This leads to accumulation of lethal free heme that damages the parasite's membrane through oxidative stress. The quinuclidine nitrogen and methylene alcohol group of quinine's molecular structure are critical to this intercalating interaction with the heme molecule.

### What are the antioxidant properties of Cinchona pubescens bark?

Methanol extracts of C. pubescens stem bark demonstrate potent DPPH• radical scavenging with an IC50 of 14.86 µg/mL and ABTS•+ scavenging at IC50 12.04 µg/mL, both significantly superior to the reference antioxidant α-tocopherol (vitamin E) at 37.15 and 38.45 µg/mL, respectively. The primary antioxidant constituent is p-hydroxybenzoic acid, present at 40.06 mg/g in methanol extract. Additional antioxidant mechanisms include metal ion chelation and phosphomolybdenum reduction capacity.

### What is the difference between Cinchona pubescens and pharmaceutical quinine?

Cinchona pubescens is the whole plant species whose bark contains a complex mixture of quinoline alkaloids, phenolics, and other phytochemicals at variable concentrations (6–15% total alkaloids). Pharmaceutical quinine is a purified, isolated alkaloid extracted from Cinchona bark via ethanol extraction and silica gel chromatography, standardized to precise concentrations for controlled medical dosing (e.g., 650 mg quinine sulfate per dose). Using whole bark preparations instead of pharmaceutical quinine introduces unpredictable alkaloid levels, increasing the risk of both underdosing (treatment failure) and overdose toxicity.

### Does Cinchona pubescens interact with antimalarial medications like artemisinin or atovaquone-proguanil?

Concurrent use of Cinchona pubescens with prescription antimalarials may increase the risk of additive toxicity and cinchonism (quinine toxicity symptoms including tinnitus, vision changes, and cardiac arrhythmias). Medical supervision is essential if combining Cinchona-based supplements with pharmaceutical antimalarial drugs, as both contain active alkaloids that work through similar mechanisms. Patients taking prescription malaria treatments should consult their healthcare provider before using Cinchona preparations.

### What is the most bioavailable form of Cinchona pubescens—bark extract, whole bark powder, or standardized alkaloid extract?

Standardized extracts containing quantified quinine and quinidine alkaloid content generally provide more consistent bioavailability than whole bark powder, though extraction methods significantly affect absorption rates. Methanol and ethanol extracts have demonstrated superior antioxidant capacity (IC50 values as low as 14.86 µg/mL for DPPH radical scavenging) compared to aqueous preparations. The specific formulation, particle size, and accompanying excipients influence how effectively the body absorbs and utilizes Cinchona's active compounds.

### Who should avoid Cinchona pubescens supplementation due to contraindications or sensitivity risks?

Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, cardiac arrhythmias, or tinnitus/hearing loss should avoid Cinchona pubescens, as quinine alkaloids can trigger hemolytic episodes and worsen cardiovascular or auditory symptoms. Pregnant and breastfeeding women should not use Cinchona supplements due to potential teratogenic effects and alkaloid transfer through breast milk. People with hypersensitivity to quinoline alkaloids or a history of cinchonism should also avoid this ingredient entirely.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*